Preclinical models show that LILRB2 blockade reprograms myeloid cells to a pro-inflammatory phenotype, enhances MHC-II and CD86 expression, and synergizes with anti–PD-1 therapy to improve T cell infiltration and tumor regression (157, 158). The gene discussed is CD86; the disease is neoplasm.